Background: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD).
Several models predict the conversion of atrophic AMD to NVAMD, each using the Age Related Eye Diseases Study (AREDS) classification of AMD [4] [5] [6] [7] [8] . The more complex model in AREDS Report No. 17 [6] , evaluated the eyes of 3212 participants, utilizing drusen severity and pigmentary abnormalities at baseline. The authors proposed a 9-step severity scale that combined a 6-step drusen area scale with a 5-step pigmentary abnormality scale. The 5-year risk of progression to advanced AMD varied from <1 % in Steps 1 and 2 to 43.5 % in Step 9 [6] . Nonetheless, the scale more accurately predicts central geographic atrophy (43.5 % in Step 9) than NVAMD (4.8 % in Step 9, but 21.1 % in the less severe Step 8) [6] . A simplified severity scale in AREDS Report No. 18 used large drusen and pigmentary changes in a 0-4 scale and demonstrated, when both were present bilaterally, the 5-year incidence of advanced AMD in at least one eye was 47.3 % [7] . While a top score of 4 identified 67.8 % of 5-year progressors to advanced AMD, it identified only 36.5 % progressing to NVAMD [7] .
Blue Mountains Eye Study investigators [8] , using an AREDS simplified severity scale, found a generalized estimating equation model showed 61.5 % of patients with bilateral drusen ≥125 μm and bilateral retinal pigment epithelial changes progressed to advanced AMD over 10 years. Assuming 70 % of those advanced AMD cases were neovascular [2] , approximately 43 % of NVAMD cases would be identified. This converts to (57.0 % × 161,754 cases=) 92,200 new NVAMD patients aged ≥65 in the US not identified by phenotypic markers annually [1] [2] [3] .
Multiple advances in AMD genetics have been made over the last decade [9] [10] [11] [12] [13] [14] [15] [16] [17] . A report by Seddon et al. [12] , created models predicting advanced AMD development. They approach include age, gender, education, smoking, body mass index, single nucleotide polymorphisms in the CFH, ARMS2/HTRA1, C3, C2, and CFB genes, as well as important markers discovered through two large genome-wide association studies [4, [13] [14] [15] [16] . With the inclusion of cholesterol metabolic markers CETP, LIPC and ABCA1, the progression prediction to advanced disease within 10 years achieved unparalleled accuracy (C = 0.90) [4] . Using this model for a dichotomous risk score ("risk" vs "non risk"), Yu et al. [4] , showed the 5-year progression of Category 3 AMD cases to advanced AMD could be predicted with both sensitivity and specificity over 80 %; sensitivity over 10 years was ≥90 %. There was a 10-year 20 % progression to neovascular AMD (Table 1 ) using phenotypic and genotypic markers, but they identified 90 % of people progressing to neovascular AMD [4] .
Neovascular AMD therapy
Intravitreal ranibizumab therapy for NVAMD is among the greatest medical advances over the decade [18] [19] [20] [21] [22] [23] [24] . Earlier therapy has a better visual prognosis than later therapy [20] . Thus, it is hoped greater risk awareness will allow patients to seek earlier care.
Considering the importance of earlier ranibizumab therapy, the authors undertook a Value-Based Medicine ® (VBM) [22] [23] [24] , societal, cost-utility analysis to assess the patient preference-based, comparative effectiveness and cost-effectiveness (cost-utility) of genetic testing for NVAMD.
Methods
Features associated with genetic testing for NVAMD, and the economic modeling assumptions used are listed in Table 2 . Comparative effectiveness quantified the incremental patient value gain (improvement in quality-of-life and/or length-of-life), though length-of-life change was not included, since better vision has not been well shown to lengthen life. Outcomes were measured in: (1) percent value gain, and (2) quality-adjusted life-year (QALY) gain [18, 20, [22] [23] [24] [25] . QALY gain was calculated by multiplying: (utility gain) × (years of interventional benefit). Financial metrics include: (1) cost-utility ratio, $/QALY, or dollars expended per QALY gained, associated with genetic testing-enabled, early-treatment ranibizumab for NVAMD, and (2) societal costs.
AMD demographics
The AREDS Research Group [5] [6] [7] defined four categories of AMD and showed oral supplements decrease the progression of Category 3 AMD (macular drusen ≥125 µm) to NVAMD, though not from Category 3 to central geographic atrophy. Yu and colleagues [4] refined the AREDS four-category model to a five-category model, separating AREDS [5] [6] [7] advanced AMD cases into central geographic atrophy (Category 4) and NVAMD (Category 5) in their genotypic/phenotypic study of AMD. Approximately 1.54 million people had NVAMD in the 
Genetic profiles
High-risk = homozygous on all genetic loci for the alleles that increase the risk of advanced AMD Medium-risk = heterozygous on genetic loci for the alleles that increase/decrease the risk of advanced AMD Low-risk = homozygous on all genetic loci for alleles that decrease the risk of advanced AMD As per Yu et al. [4] , all genes listed above are assumed to be tested for. This conservative assumption likely biases against the financial value gain and cost-effectiveness by increasing what will likely be decreased genetic costs in the future Progression to neovascular AMD Incremental, 10-year progression rate to neovascular AMD for Category 3 AMD patients with: a past smoking history, BMI of 25-29, normal fellow eye and greater than a high school education [4] Genetic profile 10-year progression Percent of progressors detected
High-risk 26% 90%
Medium-risk 3% 9%
Low-risk <1% 1%
Among people with Category 3 AMD, 20 % will progress to neovascular AMD over 10 years [4] . (SNP = single nucleotide polymorphism, * = decreased chance of progression to neovascular AMD, BMI = basal metabolic index)
Neovascular AMD therapy
Clinical features, MARINA study [18, 20, 23] All participants had minimally classic or occult, subfoveal choroidal neovascularization The 0.5 mg ranibizumab dose was more effective than the 0.3 mg dose, and was thus the dose approved by the Food & Drug Administration and used in the current analysis [18] Treatment cohort (0.5 mg ranibizumab) mean vision: MARINA Study for years 1 and 2, then LOCF (last observation carried forward) of clinical trial data for years 3-12 [23] Eligible, MARINA sham cohort patients were treated with ranibizumab following the end of the randomized portion of the trial after 24 months. Thus, sham treatment, control cohort data utilized mean vision in the MARINA Study [18] for years 1 and 2, and a Lineweaver-Burke plot metaanalysis control cohort from six randomized, neovascular AMD clinical trials for years 3-12 of sham therapy [25] Adverse event disutility QALYs, a total of 0.045 QALY, were used to calculate adverse event QALYs subtracted from total patient value gain
The average participant received 22 × 0.05 cc intravitreal injections, given approximately monthly, over 2 years Mean life expectancy: 12 years for the control and ranibizumab study cohorts [49] [18, 20, 22, 23] The patient value and financial value gains are those associated with genetic screening for neovascular AMD making possible the incremental earlier detection and earlier ranibizumab therapy for neovascular AMD Model timeline: 12 years = mean life expectancy for average neovascular AMD patient [18] Baseline vision in the early-treatment, ranibizumab therapy cohort was 20/40-20/80. Final vision outcome was 20/40 -1 [20] 20/40-1 vision in each eye equates with a utility of 0.789 [30, 39] Baseline vision in the late-treatment, ranibizumab therapy cohort was 20/160-20/320. Final vision outcome was 20/160
+2
. [20] 20/160 +2 vision in each eye equates with a utility of 0.0.658 [29, 30] Loss of vision in a first eye results in a utility loss of 0.0398 [35] The incremental cost-utility analysis per patient utilizes the incremental patient and incremental financial value gains associated with early-treatment ranibizumab therapy (baseline treatment vision 20/40-20/80) for neovascular AMD versus late-treatment ranibizumab therapy (baseline treatment vision of 20/160-20/320) [20] The costs of genetic screening were compared with the patient value gains and cost savings conferred by early-treatment ranibizumab therapy (versus late-treatment ranibizumab therapy) made possible by genetic screening
The direct ophthalmic medical treatment costs were the same in the early-treatment, ranibizumab therapy and late-treatment, ranibizumab therapy cohorts, and therefore were not considered incremental costs
Only Category 3 AMD eyes in patients who were 65 years of age were tested with genetic screening 22.5% of baseline Category 3 cases have a high-risk genetic profile to develop neovascular AMD [4] The phenotypic appearance of Category 3 AMD determines the use of AREDS supplement therapy to decrease the incidence of progression to neovascular AMD [5] . Since the use of AREDS supplements in Categories 1 and 2 AMD has not yet been shown to reduce progression to neovascular AMD [5] . Genetic screening was not presumed to be of benefit to detect whether to use AREDS supplements at an earlier stage than Category 3 AMD Genetic testing of Category 4 AMD patients for the development of more severe atrophic changes was not presumed to be of benefit Genetic testing was not presumed to be of benefit if one eye was already affected by neovascular AMD or advanced atrophic AMD Patients underwent genetic screening at age 65, since only 5.6 % of neovascular AMD develops in patients under the age of 65 years [18] Baseline time: First presentation for neovascular AMD occurs at a mean age of 75 years, as per a combination of multiple clinical trials dealing with therapy for neovascular AMD [18-20, 23, 24, 50, 51] The outcomes included the QALY (quality-adjusted life-year) gain, percent patient value (quality-of-life) gain, and the CUR (cost-utility ratio), or dollars expended per QALY gained ($/QALY) [22] All eyes with neovascular AMD were presumed treated with ranibizumab, including cases presenting with bilateral disease Time tradeoff utilities were derived from a database of over 1100 ophthalmic patients with respective levels of vision loss [22] [23] [24] [30] [31] [32] [33] [34] [35] [36] [37] [38] Cost perspectives: societal and 3rd party insurer
The societal cost perspective included those saved by the better mean vision outcome associated with early-treatment ranibizumab therapy versus late-treatment ranibizumab therapy. They include: (1) direct ophthalmic medical costs = AMD genetic testing costs + incremental annual ophthalmic examination and annual optical coherence tomography costs, (2) direct non-ophthalmic medical costs saved = decreased depression costs, decreased trauma costs, decreased Skilled Nursing Facility costs, decreased nursing costs and other, as yet unidentified, medical costs [40] . (3) direct non-medical costs (caregiver) saved [41] and (4) indirect medical (employment) costs saved [3, 42] The 3rd party insurer cost perspective includes: (1) direct ophthalmic medical costs expended and (2) direct non-ophthalmic medical costs saved
Cost basis: 2012, average, national, Medicare Fee Schedul Net present value (NPV) analysis discounted patient value outcomes and costs at a 3 % annual rate. All costs were converted to 2012 US real dollars [22] A combined-eye model, a weighted average of first-eye and second-eye models, was utilized to calculate QALY gain per early-treatment case over late-treatment case [23, 24] Taking into account the annual conversion rate, the QALY gain and financial value gain accrual rate of 1st eyes with NVAMD was 85.3 % that of 2nd eyes Second eyes in the per patient, early treatment benefit from ranibizumab were assumed to have the same visual outcome as treated first eyes
For the overall Category 3 cohort undergoing genetic testing, the early-treatment ranibizumab QALY gain and costs per person were multiplied by: (Percent of first eyes with presenting vision ≤20/160, or 78.0 %) × (Percent of second eyes with presenting vision ≤20/160 = 62.2 %) × (Sensitivity of genetic testing with phenotypic features for detecting 10-year conversion to NVAMD = 90 %). Thus, overall Category 3 cohort results average (78.0 % × 62.2 % × 90 % =) 43.7 % × (per patient value and financial value outcomes)
Conversion rates of second eyes to neovaoscular AMD with Markov modeling demonstrated the patient value (QALY gain)
It was assumed that the majority of patients converted to neovascular in one eye first and thus treated with ranibizumab initially in this first eye, though a small number of cases might have present with bilateral neovascular AMD. This assumption is conservative and biases against the analysis by decreasing the overall patient and financial gains AMD age-related macular degeneration, NVAMD neovascular age related macular degeneration, QALY quality-adjusted life-year, CUR cost-utility ratio, MARINA Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-Related Macular Degeneration, SNP single nucleotide polymorphism US in 2012 [2, 3] . Central geographic atrophy (AREDS Category 4) in at least one eye was present in 1.24 million, and 8.34 million had drusen ≥125 µm (AREDS Category 3). The 944,000 people aged 65 years with Category 3 drusen (≥125 µm) annually were those who were theoretically screened in our cost-utility model [2, 3] . Fifteen-year, incidence data from the Beaver Dam Study [26] suggest approximately 171,350 new cases of NVAMD develop annually in the US. Among these, 5.6 % in the Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular AMD (MARINA) Study [18, 20] presented before age 65. We excluded that percentage from our analysis since our model assumed genetic testing at age 65, leaving 161,754 annual new cases.
Yu et al. [4] , noted 20 % of Category 3 patients progressed to NVAMD (Category 5 AMD) over 10 years (Table 1 ). They also found 22.5 % (343/1527) of Category 3 patients had a high-risk genetic profile (homozygous for genetic loci on relevant alleles). Among progressors to NVAMD, 90 % had a high-risk genetic profile [4] . Thus, genetic testing for Category 3 AMD patients identified 90 % of progressors to NVAMD, 47 % higher than the 43.0 % identified over 10 years in the Blue Mountains Study [8] .
Utility analysis
The quality-of-life associated with AMD has been quantified using time tradeoff utility analysis [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Utility anchors are 1.00 (normal bilateral vision permanently) and 0.00 (death). Vision utilities correlate most highly with acuity in the better-seeing eye, rather than the underlying disease [28] . As vision in the better-seeing eye decreases, the associated utility decreases [27] [28] [29] [30] [31] [32] [33] [34] [35] . Vision of no light perception bilaterally has an associated utility of 0.26 [30] .
Ophthalmic utilities are valid [32] , reliable [33] , and negligibly affected by systemic comorbidities [34] . The Wills Eye Institute Institutional Review Board approved utility acquisition.
Ophthalmologists underestimated the quality-of-life associated AMD levels by 96-750 % compared to AMD patients, with community utility estimates even more disparate [31] . Thus, VBM cost-utility analyses use patient utilities [22] . Utilities herein were derived from a >1100 direct interview, vision utility database from the Center for Value-Based Medicine ® [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Value-Based Medicine

®
Value-Based Medicine ® (VBM) integrates the highest level, evidence-based, clinical trial data with standardized inputs, including: (1) time tradeoff utilities, (2) patient utility respondents, (3) a national Medicare Fee Schedule, and (4) societal and 3rd party insurer cost perspectives [22] [23] [24] . VBM has been used extensively in ophthalmology, especially for AMD interventions [22-24, 36, 37] .
Originated at the Center for Value-Based Medicine ® and based upon primary, ophthalmic patient data, the first-eye model assumes vision loss occurs in one eye, while the fellow eye has good vision [22] [23] [24] 36] . In this instance, full patient value gain is not accrued until the fellow eye also develops NVAMD. Utility data from Center for Value-Based Medicine files demonstrate a mean utility difference of 0.0398 between unilateral good vision and 20/40-20/80 vision in the second eye, versus unilateral good vision and ≤20/160 vision in the second eye. This utility gain was weighted to appropriate first-eye model instances herein.
The second-eye model assumes first-eye vision has been lost and the second eye is affected [22] [23] [24] 36] . Thus, greater patient value gain occurs with ranibizumab therapy. The combined-eye model used here integrates weighted first-eye model and second-eye models [22, 24] . Extrapolation of data from Barbazetto and colleagues [39] with Markov modeling (TreeAgePro for Healthcare 2012, Williamstown, MA, USA) showed 82 % of patients with unilateral NVAMD in the MARINA/ANCHOR trials developed bilateral NVAMD within 5 years, rising to 96 % by 12 years, the model timeline (Table 3) .
Patient value gain
Shah and DelPriore [25] modeled the natural course of untreated NVAMD using control cohorts from six randomized, NVAMD trials. In a meta-analysis using Lineweaver-Burke plots, they demonstrated mean vision loss to 20/640 over 8-9 years, after which vision stabilized. Increasing time since NVAMD highly correlated with increasing vision loss.
A double-blind, randomized, clinical trial, MARINA participants had 20/80 baseline vision in both ranibizumab-treatment and sham-treatment cohorts. The 24-month, mean, ranibizumab-treatment cohort vision was 20/63, while mean sham-treatment vision was 20/160 −2 [18, 20] . Shah and DelPriore data [25] were employed to model MARINA 25-144 month, non-randomized sham results since many sham-treatment patients were allocated to ranibizumab therapy after month 24. Treatment cohort data for months 25-144 were modeled in a LOCF (last observation carried forward) fashion. Twelve years was selected as the model length since this was the average life expectancy of the average NVAMD patient.
An analysis of baseline vision in 50 consecutive Pennsylvania/New Jersey/Delaware patients presenting with first-eye NVAMD in the vitreoretinal practice of author GCB since 2010 was undertaken. The mean, baseline, first-eye vision was 20/182, while that in the fellow eye was 20/47. Overall, 78 % (39/50) presented with vision ≤20/200 in the first eye. Only 18 % (9/50) had first-eye vision ≥20/80 vision at presentation (Table 4 ).
An analysis of 98 consecutive patients presenting with second-eye NVAMD revealed a mean vision of 20/94. Overall, 62.2 % had vision ≤20/160. The vision was ≥20/80 in 37 % of eyes (Table 4) .
Critical to our analysis, the excellent report by Boyer et al. [20] ) [20] . Total patient value gains (Table 4) , to account for those eyes presenting with ≤20/160 vision and other parameters, had an overall multiplier of 78 % (1st eyes presenting with vision ≤20/160) × 62.2 % (2nd eyes presenting with ≤20/160) × 85.7 % (combined-eye multiplier to account for NVAMD conversion to both eyes) × 90 % (genetic testing sensitivity) = 37.4 %. Adverse events disutilities were subtracted in early-treatment and late-treatment cohorts for months 1-144 [23] .
Costs
The mean, incremental, 12-year, direct, ophthalmic medical costs included genetic testing/monitoring. Ranibizumab therapy costs were excluded since they were assumed similar for early-treatment and late-treatment cohorts, though differences were analyzed in the sensitivity analysis.
Based upon work by Yu et al. [4] , genetic testing costs are shown in Table 5 . Compounded from $1461 at the time of genetic testing (age 65) to base-case age 75 at the initiation of ranibizumab therapy, they totaled $1906. A $299 cost for an extra, annual, ophthalmic examination and optical coherence tomogram (three/year rather than two/year) was included in the genetic costs for the 22.5 % [4] of genetic-screened high-risk patients progressing to NVAMD. The total cost for genetic testing/monitoring of Stage 3 AMD patients was $2205 per capita.
The base-case scenario shows that 30.3 Category 3 AMD patients required screening/monitoring to facilitate one early-treatment. The total cost of screening/ monitoring for each early-treatment patient was therefore $66,873 (30.3 × $2205).
Twelve-year negative costs accrued against genetic testing/monitoring costs [4, 20, [39] [40] [41] . Costs saved by earlytreatment, vs. late-treatment (Table 6) , are addressed below [39] [40] [41] .
Javitt and colleagues [39] demonstrated increased direct, non-ophthalmic, medical costs for depression, trauma, Skilled Nursing Facilities, nursing homes and unidentified entities associated with vision loss (Table 6) . Baseline, year 1 and year 2 prevalences are based upon primary data [39] , while years 3-12 are based upon the average incidence of conversion to neovascular during years 1 and 2, using a last observation carried forward (LOCF) methodology with Markov modeling AMD age-related macular degeneration 
This 12-year cost gained by improving vision per earlytreatment patient is (−$40,914) ( Table 6 ). Schmier and associates [40] reported increasing caregiver costs associated with decreasing levels of vision. Early-treatment ranibizumab therapy resulted in a 12-year, (−$172,443) caregiver cost saving vs. late-treatment therapy (Table 6) .
Vision loss decreases employment by 45.6 % and hourly wage loss by 32.5 % referent to age-matched normals, resulting in 36.7 % of normal earnings (Table 6 ) [41] . Integrating age-related, US employment levels, early-treatment ranibizumab therapy accrued a 12-year employment cost gain of (−$14,098) [41] .
Results
Patient value gain
The mean MARINA, early-treatment, 20/40 −1 vision outcome correlated with a 0.789 utility, while late-treatment 20/160 +2 vision correlated with a 0.658 utility (Table 7) 
Costs
Direct ophthalmic medical costs for early-treatment vs. late-treatment ranibizumab therapy were assumed the same, thus excluded in the base case analysis, but addressed in the sensitivity analysis.
Assuming one early-treatment case per 30.3 genetically screened cases, the base-case genetic testing/monitoring cost for each early-treatment case was $66,873 (Table 6 ).
The incremental negative cost for each early-treatment ranibizumab patient was (−$227,455) ( Table 6 ). With genetic testing/monitoring costs for Category 3 patients screened of $66,873 for each incremental early-treatment case, the overall societal cost per early-treatment case was (−$160,582) ( Table 6 ).
The national, direct ophthalmic cost for genetic testing/monitoring for an annual cohort of 944,400 Category 3 AMD patients million was $2.082 billion. Total negative costs were $7.083 billion. This resulted in a 12-year, financial return-on-investment (ROI) of 240 % referent to genetic testing/monitoring costs. An incremental $260 million societal saving occurred for each 1 % of patients undergoing early-treatment ranibizumab therapy. When genetic testing facilitated an incremental 12,965 (8.0 %) of the 161,754, annual NVAMD patients in the US to undergo early-treatment ranibizumab therapy, an overall, net financial gain for society accrues at the rate of $160,582 per additional early-treatment patient.
The financial ROI distribution, assuming that genetic testing for 30.3 Category 3 AMD cases resulted in one incremental early-treatment case is shown in Table 8 . The negative cost for each patient screened (cost of $2205) was (−$7500), an overall societal cost of (−$5295), also a 240 %, 12-year societal ROI. The ROI offset Medicare screening costs by 35 %, Medicaid costs by 63 % and commercial insurer costs by 22-24 %. Patients had the greatest ROI for out-of-pocket genetic testing costs, a net $6725. This converted to a 12-year 16,945 % ROI.
Cost-utility ratio (CUR)
$144,000/QALY For a $144,000/QALY CUR, the upper limit of cost-effectiveness in the US according to World Health Organization criteria [43] , an incremental 4.1 % of annual NVAMD patients were required to undergo genetic testing-enabled, earlytreatment, ranibizumab therapy. This 4.1 % converts to 6634 patients among the 161,754 annual cohort of new NVAMD patients, 92,200 of whom are not identified as high risk to develop NVAMD by phenotypic features alone (Table 9) [1-3, 9]. It also equates to 1 per 142 of the 944,000 Category 3 AMD patients screened at age 65 annually. For a 3rd party insurer CUR of $144,000/QALY, an increment of 10.1 % of all annual NVAMD patients had to undergo early-treatment for cost-effectiveness (Table 10) .
For a $100,000/QALY CUR, the upper limit of costeffectiveness commonly utilized in the US [22] , an incremental 4.5 % of annual NVAMD patients were required to undergo early-treatment, ranibizumab therapy for cost-effectiveness (Table 9 ). For a 3rd party insurer CUR of $100,000/QALY, an incremental 13.2 % of all annual NVAMD patients had to undergo early-treatment for cost-effectiveness (Table 10) .
Sensitivity analysis
Sensitivity analysis (Table 11) showed decreasing age made genetic testing considerably less cost-effective (age 40 societal CUR = $1,088,253/QALY) and 3rd party insurer CUR = $231,137/QALY). Deleting extra ophthalmic monitoring costs had negligible effect, while decreasing genetic testing price improved cost-effectiveness. If the cost of ranibizumab therapy for early-treatment cases is twice that of the ranibizumab cost for late-treatment cases, an increment of approximately 6.0 % (9700) of NVAMD cases undergoing early-treatment ranibizumab therapy is required for genetic testing to be cost-effective using WHO criteria.
Discussion
Our analysis demonstrated, using MARINA Trial data [20] , that each incremental, early-treatment, ranibizumab case of NVAMD conferred a combined-eye model, 14.1 % quality-of-life improvement, versus a 4.2 % quality-of-life improvement with late-treatment (baseline vision of 20/160-20/320) ( Table 7) , a 10.0 %, incremental, patient value gain. The net, societal, financial ROI was $160,582 per early-treatment case, a net $5295 ROI per patient screened.
While the US has no formal, cost-effectiveness upper limits, interventions costing ≤$100,000/QALY are generally believed cost-effective [22] . Formal World Health Organization standards indicate interventions costing ≤3× GDP per capita (~US $144,000) per DALY (disability-adjusted life-year), a metric similar to the QALY, are cost-effective (Tables 9, 10) [42] . Screening is still costeffective if only 4.1 % overall NVAMD cases, or 7.2 % of cases not forecast phenotypically, receive genetic testingfacilitated early-treatment ranibizumab therapy
The presence of AMD, even with good vision, can decrease a patient's quality-of-life [31] . We believe low-risk/ medium-risk genetic profiles for progression to advanced AMD, likely allay patient fears and improve patient qualityof-life. We are uncertain how a positive, high-risk genetic profile affects patient quality-of-life, but since only 22.5 % of screened patients have a high-risk profile [4] , the overall quality-of-life gain in the low-risk and medium-risk genetic profile cohorts could possibly outweigh total quality-of-life loss in the high-risk profile cohort.
Wealth of the nation
The data herein support the work of Nordhaus [43] , the Yale economist who estimated 50 % of the wealth of the United States created during the twentieth century occurred from healthcare advances. While secondary to patient value gain, the increase in national wealth associated with medical interventions is an important factor. If 12,965 (8.0 %) of the 62,279 NVAMD cohort patients not predicted phenotypically to develop NVAMD are recruited to early-treatment due to genetic testing, the cost of testing is at a breakeven point. Each patient undergoing early-treatment in addition adds $160,582 to societal wealth.
When to genetically screen
We selected the age of 65 years as the most cost-effective age for genetic screening since it encompasses 94.4 % of those who develop NVAMD [18] . As sensitivity analysis shows, the earlier genetic testing is performed, the greater the expense of testing, since analyses must account for the time value of money. Table 8 The model is a combined-eye model integrating the patient value gain and costs associated with first-eye (78.0 % presenting with vision <20/160) and second-eye (62.2 % of eyes presenting with 20/20/160 vision) ranibizumab therapy for neovascular AMD, assuming genetic testing identifies 90 % of cases that will progress to neovascular age-related macular degeneration A negative cost-utility ratio () indicates that early-treatment dominates late treatment, meaning that early-treatment accrues greater QALYs and has a positive financial return-on-investment QALY quality-adjusted life-year, $/QALY cost-utility ratio, or dollars expended/gained per QALY gained from genetic testing The societal costs perspective included the following costs: (a) direct ophthalmic medical costs, (b) direct non-ophthalmic medical costs (depression, trauma, skilled nursing facility, nursing home, other Medicare costs) + caregiver costs + employment costs saved by genetic testing leading to early-treatment, versus late-treatment, of neovascular age-related macular degeneration with intravitreal ranibizumab Direct non-ophthalmic medical costs = costs for depression, trauma, skilled nursing facilities, nursing homes and other Medicare costs
The model is a combined-eye model integrating the patient value gain and costs associated with first-eye (78.0 % presenting with vision <20/160) and second-eye (62.2 % of eyes presenting with 20/20/160 vision) ranibizumab therapy for neovascular AMD, assuming genetic testing identifies 90 % of cases that will progress to neovascular age-related macular degeneration A negative cost-utility ratio () indicates that early-treatment dominates late treatment, meaning that early-treatment accrues greater QALYs and has a positive financial return-on-investment (QALY quality-adjusted lifeyear, $/QALY cost-utility ratio, or dollars expended/gained per QALY gained from genetic testing, AMD age-related macular degeneration) Cost-utility (cost-effectiveness) ratios for Category 3 AMD patients screened for neovascular AMD resulting in incremental, early-treatment ranibizumab therapy (2012 US real dollars, combined-eye model [18] [19] [20] 22 ])
A negative cost-utility ratio (parentheses) indicates that early-treatment dominates late treatment, meaning that early-treatment accrues greater QALYs and has a positive financial return-on-investment NVAMD neovascular Age-related macular degeneration, QALY quality-adjusted life-year, $/QALY cost-utility ratio, or dollars expended/gained per QALY gained from genetic testing, US United States informal upper limit for cost-effectiveness, WHO World Health Organization upper limit for cost-effectiveness = 3× Gross Domestic Product per capita, AMD age-related macular degeneration, 3rd party third party insurer cost perspective, integrating all incremental direct medical costs associated with genetic screening for neovascular AMD, Societal societal cost perspective, including all direct ophthalmic medical, direct non-ophthalmic medical, direct non-medical (caregiver) and indirect medical (employment) costs $500 cost for genetic testing, screening at age 65 Societal
